Research
News in brief

Australian institute to study ChromaDex's Niagen ingredient in mitochondrial respiratory conditions

04-Aug-2014
Last updated on 05-Aug-2014 at 16:38 GMT - By Hank Schultz
Niagen supports mitochondrial health, ChromaDex says.
A- A+

ChromaDex Corp. announced an agreement to supply its Niagen nicotinamide riboside ingredient to the Murdoch Children’s Research Institute in Australia to enable researchers there to study the ingredient’s effects in cellular and animal models of mitochondrial respiratory diseases.

Niagen is the only commercially available form of nicotinamide riboside (NR), which is a naturally occurring vitamin B3 derivative found in milk. Published research has shown that NR is perhaps the most effective precursor to boost the co-enzyme NAD+ in the cell.  NAD+ is an important cellular co-factor for improvement of mitochondrial performance and energy.  NAD+ is essential in supporting healthy cellular metabolism including the efficient conversation of blood glucose into energy. 

Dr. David Thorburn, Mitochondrial Research group head at Murdoch Childrens Research Institute, together with Dr. Ann Frazier and Dr. Bi-Xia Ke, and supported by a grant from the Australian Mitochondrial Disease Foundation, will study the response to NR in mouse models with mitochondrial Complex I deficiency and in a range of human and mouse cell lines with impaired mitochondrial function.

In addition to Niagen, ChromaDex also supplies pTeroPure pterostilbene; ProC3G, a natural black rice containing cyanidin-3-glucoside; and Purenergy, a caffeine-pTeroPure co-crystal.  The company also performs analytical testing services and coslting services via its Spherix Consulting subsidiary.

Related topics: Research, Vitamins & premixes, Cardiovascular health, Energy, Respiratory health, Sports nutrition